Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 9.01
NVIV's Cash to Debt is ranked higher than
77% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. NVIV: 9.01 )
NVIV' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 9.01

F-Score: 3
Z-Score: 0.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -116.75
NVIV's ROE (%) is ranked lower than
53% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. NVIV: -116.75 )
NVIV' s 10-Year ROE (%) Range
Min: -775.86   Max: -360
Current: -116.75

-775.86
-360
ROA (%) -81.84
NVIV's ROA (%) is ranked lower than
52% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. NVIV: -81.84 )
NVIV' s 10-Year ROA (%) Range
Min: -1218.1   Max: 42.86
Current: -81.84

-1218.1
42.86
ROC (Joel Greenblatt) (%) -917.44
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. NVIV: -917.44 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3330.38   Max: -817.6
Current: -917.44

-3330.38
-817.6
EPS Growth (%) 273.30
NVIV's EPS Growth (%) is ranked higher than
99% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. NVIV: 273.30 )
NVIV' s 10-Year EPS Growth (%) Range
Min: 0   Max: 273.3
Current: 273.3

0
273.3
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.60
NVIV's P/B is ranked higher than
57% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. NVIV: 7.60 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 13.5
Current: 7.6

0
13.5
EV-to-EBIT -4.27
NVIV's EV-to-EBIT is ranked higher than
54% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. NVIV: -4.27 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.27

Current Ratio 3.81
NVIV's Current Ratio is ranked higher than
79% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. NVIV: 3.81 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 14.81
Current: 3.81

0.14
14.81
Quick Ratio 3.81
NVIV's Quick Ratio is ranked higher than
83% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. NVIV: 3.81 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 14.81
Current: 3.81

0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.00
NVIV's Price/Net Cash is ranked higher than
94% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. NVIV: 9.00 )
NVIV' s 10-Year Price/Net Cash Range
Min: 4.92   Max: 38.75
Current: 9

4.92
38.75
Price/Net Current Asset Value 9.00
NVIV's Price/Net Current Asset Value is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. NVIV: 9.00 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 4.92   Max: 38.75
Current: 9

4.92
38.75
Price/Tangible Book 7.70
NVIV's Price/Tangible Book is ranked higher than
67% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. NVIV: 7.70 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 4.21   Max: 19.38
Current: 7.7

4.21
19.38
Earnings Yield (Greenblatt) -23.40
NVIV's Earnings Yield (Greenblatt) is ranked lower than
51% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NVIV: -23.40 )
NVIV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -29.4   Max: 1000
Current: -23.4

-29.4
1000

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NVIV: FDA Allows InVivo Therapeutics To Expedite Enrollment For Spinal Injury Device Dec 16 2014
InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial Dec 16 2014
InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial Dec 16 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 09 2014
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical... Nov 25 2014
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical... Nov 25 2014
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for... Nov 21 2014
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for... Nov 21 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Nov 20 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Nov 18 2014
Medical Device Makers Are Cheering After Latest Victory from GOP Nov 14 2014
Media Frenzy Over InVivo's Device May Spark Rally In The Shares Nov 12 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Nov 12 2014
InVivo Therapeutics Announces Appointment of Ann Merrifield to Its Board of Directors Nov 11 2014
InVivo Therapeutics Announces Appointment of Ann Merrifield to Its Board of Directors Nov 11 2014
10-Q for Invivo Therapeutics Holdings Corp. Nov 07 2014
For InVivo, It's Finally About The Data Nov 07 2014
InVivo Therapeutics Reports 2014 Third Quarter Financial Results and Business Update Nov 05 2014
InVivo Therapeutics Reports 2014 Third Quarter Financial Results and Business Update Nov 05 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly Report Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK